The services of the Genetics Core will be utilized by both Project 1 and 2. The Genetics Core has several responsibilities for this proposal. The first is the extraction and storage of DNA from whole blood received from the five study sites. The second is the coordination of the genome wide association study (GWAS) and the validation studies. Both the DNA samples and the GWAS information will be used in both Project 1 and Project 2. DNA will also be used for follow-up SNP genotyping within the validation cohort as determined by the results of the GWAS analysis. Additional genotyping of candidate SNPs will be done for Aim 4 of Project 2. Additionally, the Genetics Core will be involved in the isolation of RNA from peripheral white blood cells (WBCs) and conduct gene expression analysis for Project 2. Whole blood will be received from five clinical sites. The Genetics Core will be responsible for extracting DNA from these samples, quality control assessment of DNA samples, sample tracking and sample storage. All samples will have specific sample identification numbers that prevent identification ofthe sample source. As a safety measure, an aliquot of all samples will be stored offsite in Dr. Israni's laboratory (Project 1). DNA samples will be separated into two cohorts, one cohort used for the initial GWAS analysis and the second cohort for SNP validation. These cohorts will contain DNA that has been isolated in the current proposal and samples obtained through this proposal. The majority of the DNA samples isolated through this proposal will be used for the creation of the validation cohort. The Genetics Core will then set up samples for and coordinate the GWAS study which will provide genetic data for Project 1 and 2. The Genetics Core will also set up samples for and coordinate the validation studies for Project 1 and 2. Additional techniques that done by the Genetics Core include candidate SNP analysis for Project 2 and quantitative PCR of expression of candidate genes, also for Project 2. Genotyping for the validation cohort will be conducted in Dr. Israni's laboratory and facilitated by the Genetics Core.

Public Health Relevance

The relevance of the Genetics Core is to facilitate the production of genotypes from patient DNA for the GWAS which will be used by both Project 1 and Project 2. This includes extraction of DNA from patient blood samples, tracking and storing DNA, and coordinating the genotyping. The Genetics Core will also provide additional genotyping of candidate genes and expression analysis for Project 2.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI070119-07
Application #
8379774
Study Section
Special Emphasis Panel (ZAI1-MFH-I)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
7
Fiscal Year
2012
Total Cost
$742,817
Indirect Cost
$77,636
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Wu, Jennifer F; Muthusamy, Amutha; Al-Ghalith, Gabriel A et al. (2018) Urinary microbiome associated with chronic allograft dysfunction in kidney transplant recipients. Clin Transplant 32:e13436
Scheibner, Aileen; Remmel, Rory; Schladt, David et al. (2018) Tacrolimus Elimination in Four Patients With a CYP3A5*3/*3 CYP3A4*22/*22 Genotype Combination. Pharmacotherapy :
Seibert, Stephan R; Schladt, David P; Wu, Baolin et al. (2018) Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 32:e13424
Snoek, Rozemarijn; van Setten, Jessica; Keating, Brendan J et al. (2018) NPHP1 (Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD. J Am Soc Nephrol 29:1772-1779
Oetting, William S; Wu, Baolin; Schladt, David P et al. (2018) Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics 19:175-184
Okour, Malek; Jacobson, Pamala A; Ahmed, Mariam A et al. (2018) Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. J Clin Pharmacol 58:628-639
Dorr, Casey R; Wu, Baolin; Remmel, Rory P et al. (2018) Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing. Pharmacogenomics J :
Dorr, Casey R; Oetting, William S; Jacobson, Pamala A et al. (2018) Genetics of acute rejection after kidney transplantation. Transpl Int 31:263-277
Dorr, Casey R; Remmel, Rory P; Muthusamy, Amutha et al. (2017) CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. Drug Metab Dispos 45:957-965
Sanghavi, K; Brundage, R C; Miller, M B et al. (2017) Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. Pharmacogenomics J 17:61-68

Showing the most recent 10 out of 44 publications